Pergolide Have Been Withdrawn from the Market in China due to Safety Risks

Recently, the State Food and Drug Administration (SFDA) of China issued a notice stating that in view of the risk of increased heart valve damage from the preparation of Pergolide mesylate, it was decided that from January 1, 2008, the production, sale, and use of the drug should be stopped by the drug manufacturing, operating and using units, and the approval certificate of the drug will also be withdrawn at the same time. Pergolide mesylate tablets, the indications are that this product is a dopamine receptor agonist and a synergistic drug for the compound levodopa preparation. Pergolide is a drug used to treat Parkinson’s disease. The safety issues of adverse reactions to severe damage to heart valves are well established. Together with its use as second-line adjuvant therapy in the later stages of Parkinson’s disease treatment. Its therapeutic status can be replaced. On March 29, the FDA declared that the drug manufacturer has voluntarily withdrawn the drug from the U.S. market. The products withdrawn from the market include the products of the original issuer Eli Lilly and Company and two generic products. There are currently two companies in China that hold the approval number for the product. Pergolide mesylate tablets […]